Sorrento Therapeutics (LTS:0L85) Scaled Net Operating Assets: -0.15 (As of Jun. 2023)


LTS:0L85 Sorrento Therapeutics Inc LTS:0L85
12 GF Score
Price $0.00
View Full Analysis

What is Sorrento Therapeutics Scaled Net Operating Assets?

Sorrento Therapeutics LTS:0L85 12 Scaled Net Operating Assets is -0.15 as of Jun. 2023. GuruFocus rates LTS:0L85 with a GF Score™ of 12/100.

Scaled Net Operating Assets (SNOA) is calculated as the difference between operating assets and operating liabilities, scaled by lagged total assets.

Sorrento Therapeutics's operating assets for the quarter that ended in Jun. 2023 was $376.06 Mil. Sorrento Therapeutics's operating liabilities for the quarter that ended in Jun. 2023 was $447.05 Mil. Sorrento Therapeutics's Total Assets for the quarter that ended in Mar. 2023 was $460.06 Mil. Therefore, Sorrento Therapeutics's scaled net operating assets (SNOA) for the quarter that ended in Jun. 2023 was -0.15.

Sorrento Therapeutics Scaled Net Operating Assets Historical Data

* Premium members only.

The historical data trend for Sorrento Therapeutics's Scaled Net Operating Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Sorrento Therapeutics Scaled Net Operating Assets Chart

Sorrento Therapeutics Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Scaled Net Operating Assets
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.65 0.48 0.46 0.35 0.09

Sorrento Therapeutics Quarterly Data
Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23
Scaled Net Operating Assets Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.24 0.29 0.10 -0.02 -0.15

LTS:0L85 vs IMUX, OCUP, KZR: Scaled Net Operating Assets Comparison

For the Biotechnology subindustry, Sorrento Therapeutics's Scaled Net Operating Assets, along with its competitors' market caps and Scaled Net Operating Assets data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Sorrento Therapeutics Scaled Net Operating Assets vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Sorrento Therapeutics's Scaled Net Operating Assets distribution charts can be found below:

* The bar in red indicates where Sorrento Therapeutics's Scaled Net Operating Assets falls into.


LTS:0L85
12GF Score
Sorrento Therapeutics Inc LTS:0L85
Scaled Net Operating Assets is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Sorrento Therapeutics Scaled Net Operating Assets Calculation

Scaled Net Operating Assets (SNOA) is calculated as the difference between operating assets and operating liabilities, scaled by lagged total assets.

Sorrento Therapeutics's Scaled Net Operating Assets (SNOA) for the fiscal year that ended in Dec. 2022 is calculated as

Scaled Net Operating Assets (SNOA)(A: Dec. 2022 )
=(Operating Assets (A: Dec. 2022 )-Operating Liabilities (A: Dec. 2022 ))/Total Assets (A: Dec. 2021 )
=(422.862-360.005)/694.818
=0.09

where

Operating Assets(A: Dec. 2022 )
=Total Assets - Cash, Cash Equivalents, Marketable Securities
=472.84 - 49.978
=422.862

Operating Liabilities(A: Dec. 2022 )
=Total Liabilities - Long-Term Debt & Capital Lease Obligation - Short-Term Debt & Capital Lease Obligation
=494.509 - 104.338 - 30.166
=360.005

Sorrento Therapeutics's Scaled Net Operating Assets (SNOA) for the quarter that ended in Jun. 2023 is calculated as

Scaled Net Operating Assets (SNOA)(Q: Jun. 2023 )
=(Operating Assets (Q: Jun. 2023 )-Operating Liabilities (Q: Jun. 2023 ))/Total Assets (Q: Mar. 2023 )
=(376.057-447.048)/460.063
=-0.15

where

Operating Assets(Q: Jun. 2023 )
=Total Assets - Cash, Cash Equivalents, Marketable Securities
=456.692 - 80.635
=376.057

Operating Liabilities(Q: Jun. 2023 )
=Total Liabilities - Long-Term Debt & Capital Lease Obligation - Short-Term Debt & Capital Lease Obligation
=654.648 - 74.187 - 133.413
=447.048

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Scaled Net Operating Assets of -0.15 mean?
Sorrento Therapeutics (LTS:0L85) has a Scaled Net Operating Assets of -0.15 as of Jun. 2023. Scaled net operating assets equals current-period operating assets less operating liabilities less prior-period total assets. View historical data on Sorrento Therapeutics and its competitors.
Is Sorrento Therapeutics' Scaled Net Operating Assets too high?
Sorrento Therapeutics' current Scaled Net Operating Assets is -0.15. Overall, Sorrento Therapeutics has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does Sorrento Therapeutics' Scaled Net Operating Assets compare to IMUX and OCUP?
Sorrento Therapeutics' Scaled Net Operating Assets of -0.15 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Scaled Net Operating Assets for a Biotechnology company?
A good Scaled Net Operating Assets depends on the Biotechnology industry context. However, Scaled Net Operating Assets should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Scaled Net Operating Assets mean?
A high Scaled Net Operating Assets can signal that a stock is expensive relative to its fundamentals. Scaled net operating assets equals current-period operating assets less operating liabilities less prior-period total assets. View historical data on Sorrento Therapeutics and its competitors. Sorrento Therapeutics's current Scaled Net Operating Assets is -0.15. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sorrento Therapeutics stock overvalued right now?
Sorrento Therapeutics (LTS:0L85) has a current Scaled Net Operating Assets of -0.15. The current Scaled Net Operating Assets is -0.15. Sorrento Therapeutics' overall GF Score™ is 12/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Scaled Net Operating Assets calculated?
Scaled Net Operating Assets is calculated from a company's financial statements. For Sorrento Therapeutics (LTS:0L85), the current Scaled Net Operating Assets is -0.15 as of Jun. 2023. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Sorrento Therapeutics Business Description

Address 4955 Directors Place, San Diego, CA, USA, 92121
Sorrento Therapeutics Inc is a clinical and commercial-stage biopharmaceutical company developing a portfolio of next-generation treatments for three major therapeutic areas: cancer, infectious disease, and pain. Its multimodal, multipronged approach to fighting cancer is made possible by its extensive immuno-oncology platforms, including key assets such as fully human antibodies (G-MAB library), immuno-cellular therapies (DAR-T), antibody-drug conjugates (ADCs), and oncolytic virus (Seprehvec). Sorrento is also developing potential antiviral therapies and vaccines against coronaviruses, including COVI-AMG, COVIDROPS, COVISHIELD, FUJOVEE (Abivertinib), and OQORY (Covi-MSC), and diagnostic test solutions, including COVITRACK and COVIMARK.
12GF Score

Get the complete analysis for LTS:0L85

Scaled Net Operating Assets is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.00
Price